Bloomfield, Connecticut, United States Cigna appeared to be the Corporate Investor, which was created in 1982. The main department of described Corporate Investor is located in the Bloomfield. The company was established in North America in United States.
The standard case for the fund is to invest in rounds with 6 partakers. Despite the Cigna, startups are often financed by U.S. Venture Partners (USVP), Designer Fund, The Vertical Group. The meaningful sponsors for the fund in investment in the same round are U.S. Venture Partners (USVP), Seven Peaks Ventures, Sanofi-Genzyme BioVentures. In the next rounds fund is usually obtained by Wellington Management, U.S. Venture Partners (USVP), Sanofi-Genzyme BioVentures.
The fund has exact preference in some founders of portfolio startups. Among the most successful fund investment fields, there are Analytics, Hospital. Besides, a startup requires to be at the age of 6-10 years to receive the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Omada Health, Prognos. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States.
Considering the real fund results, this Corporate Investor is 40 percentage points more often commits exit comparing to other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The top activity for fund was in 2017. The fund is constantly included in less than 2 deals per year.
Related Funds
| Fund Name | Location |
| APPYHIGH | - |
| BlockOG Capital | - |
| Centrosome Ventures | Atlanta, Georgia, United States |
| Hollard Insurance | Gauteng, Johannesburg, South Africa |
| Shenzhenshi Shiji Huixiang | China, Guangdong, Shenzhen |
| Southridge Capital | Connecticut, Ridgefield, United States |
| TBG Partners | Austin, Texas, United States |
| The U.S. Air Force | Randolph, Texas, United States |
| WeSai | Beijing, Beijing Shi, China |
| Yelp | California, San Francisco, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Ryse Health | $3M | 08 Apr 2022 | Arlington, Virginia, United States | ||
Prognos Health | $20M | 27 Nov 2017 | New York, New York, United States | ||
Omada Health | $50M | 14 Jun 2017 | San Francisco, California, United States |
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Ryse Health | $3M | 08 Apr 2022 | Arlington, Virginia, United States | ||
Prognos Health | $20M | 27 Nov 2017 | New York, New York, United States | ||
Omada Health | $50M | 14 Jun 2017 | San Francisco, California, United States |
